Implementation of chimeric antigen receptor (CAR) T-cell therapy in the NHS: prospects, promises and pitfalls.

Abstract

The approval, introduction, and provision of chimeric antigen receptor (CAR) T-cell therapy in the UK NHS presents a innovative and revolutionary approach in cancer treatment and management. CAR T-cell therapy is a highly specialised and personalised type of immunotherapy that involves reprogramming a patient's immune system by synthetically modifying their T-cells to specifically target and eliminate cancer cells. This therapy offers the potential to cure malignancies that were previously deemed incurable or refractory to conventional chemotherapy. CAR T-cell therapy, however, is associated with significant risks and life-threatening complications, and it entails substantial financial cost. The implementation of CAR T-cell therapy in the NHS marks a new era of personalised medicine, offering a promising approach not only for improving cancer outcomes, but for enhancing survivorship and quality of life among patients with advanced and relapsing haematologic malignancies.